川陈皮素通过下调磷酸肌醇3激酶／蛋白激酶B信号通路诱导凋亡抑制人乳腺癌细胞MCF-7增殖  

Nobiletin induces apoptosis to inhibit the proliferation of human breast cancer cell line MCF -7 via downregulating phosphatidylinositol 3 kinase/protein kinase B signaling pathway

作　　者：吴珏堃[1] 邱万寿[1] 阮莹[1] 林继宗[1] 龙梅珺[1] 李玺[1] 

机构地区：[1]中山大学第三附属医院甲状腺乳腺外科,广州510630

出　　处：《中华实验外科杂志》2016年第4期888-890,共3页Chinese Journal of Experimental Surgery

摘　　要：目的体外观察川陈皮素对乳腺癌细胞增殖的抑制作用并探讨机制。方法采用噻唑蓝（MTT）法观察川陈皮素对人乳腺癌细胞MCF-7增殖影响；Hoechst33342染色观察川陈皮素处理后细胞形态的变化；膜联蛋白V（AnnexinV）／碘化丙锭（PI）检测川陈皮素对MCF-7细胞凋亡的影响；Westernblot检测川陈皮素处理后MCF-7细胞中蛋白表达的改变。结果10μmol／L川陈皮素能明显的抑制MCF-7细胞生长（P〈0．05），抑制作用呈剂量、时间依赖关系；10、20、40μmoL／L川陈皮素处理24h后，MCF-7细胞出现细胞核皱缩，凋亡小体，并且细胞凋亡率（13．5％、37．7％、49．96％）随着川陈皮素作用浓度的增加而上升；川陈皮素能引起B细胞淋巴瘤／白血病-2相关X蛋白（bax）／B细胞淋巴瘤／白血病-2（bcl-2）比率上升（P〈0．01），磷酸肌醇3激酶（P13K）／蛋白激酶B（Akt）信号通路相关蛋白表达下降（P〈0．01）。结论川陈皮素在体外能抑制乳腺癌细胞增殖，其作用机制可能与抑制P13K／Akt信号通路从而诱导细胞凋亡有关。Objective To investigate whether nobiletin suppresses the cell proliferation of human breast cancer cell and explore the underlying mechanism. Methods Methyl thiazol tetrazolium （MTT） as- say, Hoechst 33342 stainning and Annexin V/propidium iodide （P1） were used to examine the viability and apoptosis of MCF -7 cells treated with nobiletin. Results Nobiletin of 10 μmol/L significant inhibited MCF - 7 cell proliferation （ P 〈 0.05 ） , the inhibition was revelant to dosage and time - dependant manner. After 24 hours incubated with Nobiletin of 10, 20, 40 μmol/L respectively, MCF -7 cells became shrink- age and induced apoptosis, the apoptosis rate （ 13.5% , 37.7% , 49.96% ） increased as the increasing dosage. The ratio of B cell lymphoma/leukemia - 2 （ bcl - 2 ） associated X protein/bcl - 2 was increased whereas the proteins expression of phosphatidylinositol 3 kinase/protein kinase B （PI3K/Akt） signaling pathway was decreased （ P 〈 0. 01 ）. Conclusion Nobiletin inhibits proliferation of MCF - 7 cells in vitro, which might be related with apoptosis via suppressing the protein expression of PI3K/Akt signaling pathway.

关 键 词：川陈皮素 乳腺癌 脱噬作用 磷酸肌醇3激酶/蛋白激酶B 

分 类 号：R73-36[医药卫生—肿瘤]